IP Library Granted Patent US 10,577,426
Granted Patent B2
US 10,577,426 · App. 15/962,673 · Granted Mar 3, 2020

Anti-GITR antibodies and methods of use thereof

Inventors: Ana M. Gonzalez (Cambridge, MA); Nicholas S. Wilson (Somerville, MA); Dennis J. Underwood (Jamaica Plain, MA); Volker Seibert (Lörrach, DE); Olivier Léger (Saint-Sixt, FR); Marc Van Dijk (Bilthoven, NL); Roberta Zappasodi (New York, NY); Taha Merghoub (Jersey City, NJ); Jedd David Wolchok (New York, NY); David Schaer (Mamaroneck, NY); Gerd Ritter (New York, NY); Takemasa Tsuji (Williamsville, NY)
Assignees: AGENUS INC.; MEMORIAL SLOAN-KETTERING CANCER CENTER; LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
C07K16/2878A61K35/17C07K16/2809G01N33/502A61K2039/507C07K2317/24C07K2317/34C07K2317/56C07K2317/565C07K2317/75C07K2317/76C07K2317/92G01N2333/70578Y02A50/386
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,577,426
App. No.
15/962,673
Granted
Mar 3, 2020
Kind
B2
Abstract

The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Claims (38)

1. An isolated nucleic acid molecule encoding:

(a) a VH comprising the amino acid sequence of SEQ ID NO: 206; and/or

(b) a VL comprising the amino acid sequence of SEQ ID NO: 208.

2. The isolated nucleic acid molecule of claim 1 , wherein:

(a) the amino acid sequence of the VH consists of the amino acid sequence of SEQ ID NO: 206; and/or

(b) the amino acid sequence of the VL consists of the amino acid sequence of SEQ ID NO: 208.

3. The isolated nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes:

(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 567; and/or

(b) a light chain comprising the amino acid sequence of SEQ ID NO: 576.

4. The isolated nucleic acid molecule of claim 3 , wherein:

(a) the amino acid sequence of the heavy chain consists of the amino acid sequence of SEQ ID NO: 567; and/or

(b) the amino acid sequence of the light chain consists of the amino acid sequence of SEQ ID NO: 576.

5. The isolated nucleic acid molecule of claim 1 , wherein the nucleic acid molecule further encodes a human IgG1 heavy chain constant region and/or a human kappa light chain constant region.

6. The isolated nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes:

(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 567; and

(b) a VL comprising the amino acid sequence of SEQ ID NO: 208.

7. The isolated nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes:

(a) a VH comprising the amino acid sequence of SEQ ID NO: 206; and

(b) a light chain comprising the amino acid sequence of SEQ ID NO: 576.

8. An isolated vector comprising the nucleic acid molecule of claim 1 .

9. A host cell comprising the isolated nucleic acid molecule of claim 1 .

10. A method of producing an antibody that specifically binds to human GITR comprising culturing the host cell of claim 9 so that the nucleic acid molecule is expressed and the antibody is produced.

11. A host cell comprising:

(a) a first nucleic acid molecule encoding a VH comprising the amino acid sequence of SEQ ID NO: 206; and (b) a second nucleic acid molecule encoding a VL comprising the amino acid sequence of SEQ ID NO: 208.

12. The host cell of claim 11 , wherein the amino acid sequence of the VH consists of the amino acid sequence of SEQ ID NO: 206; and/or the amino acid sequence consists of the VL consists of the amino acid sequence of SEQ ID NO: 208.

13. The host cell of claim 11 , wherein the first and second nucleic acid molecules further encode a human IgG1 heavy chain constant region and/or a human kappa light chain constant region, respectively.

14. The host cell of claim 11 , wherein the first nucleic acid molecule encodes a heavy chain comprising the amino acid sequence of SEQ ID NO: 567.

15. The host cell of claim 11 , wherein the second nucleic acid molecule encodes a light chain comprising the amino acid sequence of SEQ ID NO: 576.

16. The host cell of claim 11 , wherein:

(a) the first nucleic acid molecule encodes a heavy chain comprising the amino acid sequence of SEQ ID NO: 567; and

(b) the second nucleic acid molecule encodes a light chain comprising the amino acid sequence of SEQ ID NO: 576.

17. The host cell of claim 16 , wherein:

(a) the amino acid sequence of the heavy chain consists of the amino acid sequence of SEQ ID NO: 567; and/or

(b) the amino acid sequence of the light chain consists of the amino acid sequence of SEQ ID NO: 576.

18. The host cell of claim 11 , wherein the first nucleic acid molecule and the second nucleic acid molecule are comprised within a single vector.

19. The host cell of claim 11 , wherein the first nucleic acid molecule and the second nucleic acid molecule are comprised within separate vectors.

20. The host cell of claim 11 , wherein the host cell is a CHO cell.

21. A method of producing an antibody that specifically binds to human GITR comprising culturing the host cell of claim 11 so that the nucleic acid molecule is expressed and the antibody is produced.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2018
From: GONZALEZ, ANA M.; WILSON, NICHOLAS S.; UNDERWOOD, DENNIS J.
To: AGENUS INC.
Reel/Frame 045678/0359 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2018
From: 4-ANTIBODY AG
To: AGENUS INC.
Reel/Frame 045678/0560 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2018
From: LÉGER, OLIVIER; SEIBERT, VOLKER; VAN DIJK, MARC
To: 4-ANTIBODY AG
Reel/Frame 045678/0575 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2018
From: RITTER, GERD; TSUJI, TAKEMASA
To: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
Reel/Frame 045678/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2018
From: ZAPPASODI, ROBERTA; MERGHOUB, TAHA; WOLCHOK, JEDD DAVID; SCHAER, DAVID
To: MEMORIAL SLOAN-KETTERING CANCER CENTER
Reel/Frame 045678/0605 →
Continuity (4)
Division 14724452 · May 28, 2015
Provisional Application 62161250 · May 13, 2015
Provisional Application 62004071 · May 28, 2014
Related Publication 20190010239A1 · Jan 10, 2019